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Abstract
Hepatocellular carcinoma (HCC) is best treated by liver 
transplantation, but the applicability of transplantation is 
greatly limited. Tumor resection in partial hepatectomy is 
hence resorted to. However, in most parts of the world, 
only 20%-30% of HCCs are resectable. The main reason 
for such a low resectability is a future liver remnant 
too small to be sufficient for the patient. To allow more 
HCC patients to undergo curative hepatectomy, a 
variety of ways have been developed to increase the 
resectability of HCC, mainly ways to increase the future 
liver remnants in patients through hypertrophy. They 
include portal vein embolization, sequential transarterial 
chemoembolization and portal vein embolization, staged 
hepatectomy, two-staged hepatectomy with portal vein 
ligation, and Associating Liver Partition and Portal Vein 
Ligation in Staged Hepatectomy. Herein we review, 
describe and evaluate these different ways, ways that 
can be life-saving.
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Core tip: There are different ways to increase the 
resectability of hepatocellular carcinoma by increasing 
the volume of the future liver remnant (FLR) through 
hypertrophy. Portal vein embolization features the the 
embolization of the ipsilateral side of the portal vein 
which supplies the liver lobe harboring the tumor, 
either in an open or percutaneous manner. Sequential 
transarterial chemoembolization and portal vein embo-
lization is a way to augment the effect of portal vein 
embolization and prevent tumor progression. Staged 
hepatectomy is mainly for liver tumors with bilobar 
involvement and colorectal liver metastasis and is often 
aided by effective adjuvant chemotherapy. Its aim is to 
strike a balance between complete tumor removal and 
preservation of the FLR. Two-staged hepatectomy with 
portal vein ligation is also mainly for liver tumors with 
bilobar involvement and colorectal liver metastasis. In 
the first-stage operation, tumor in the liver portion which 
is designated as the FLR is cleared, and portal vein 
ligation is performed. The liver parenchyma is transected 
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only in the second-stage operation. Associating Liver 
Partition and Portal Vein Ligation in Staged Hepatectomy 
is used to speed up hypertrophy in the hope that the FLR 
will grow large enough for a safe hepatectomy before 
tumor progression occurs. It features right portal vein 
ligation and in-situ splitting of the intended transection 
surface down to the inferior vena cava. In the first-stage 
operation, the anterior approach is encouraged and the 
Pringle maneuver is discouraged, and the hilar plate is 
left untouched.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer and the most common primary liver 
malignancy[1,2]. Most cases of HCC in Asia are related to 
hepatitis B, which is prevalent in the region[3]. The best 
treatment for HCC is liver transplant because it removes 
both the tumor and the diseased liver, and a 5-year 
post-transplant survival rate of > 70% is expected[4-7]. 
Unfortunately, its applicability is limited by the shortage 
of liver grafts[8]. Moreover, only patients who have HCC 
within selection criteria (e.g., the Milan criteria[9], the 
University of California, San Francisco criteria[10] are 
eligible for liver transplant. A study reported that for 
patients with HCC within the Milan criteria, the 5-year 
survival rate was 81% with living donor liver transplant 
and 72.8% with partial hepatectomy[11]. In the face of 
perpetual liver graft shortage, hepatectomy remains 
an important curative measure as it can achieve a 
satisfactory survival outcome.
Hepatectomy has been evolving and is getting 
more technically challenging as surgeons are pushing 
limits. They are trying to operate on HCCs larger and 
larger and with more and more nodules, but a R0 
resection is always the ultimate goal. The applicability 
of hepatectomy is often limited by an inadequate future 
liver remnant (FLR) or a marginal liver, especially in 
patients with underlying hepatitis or cirrhosis. The 
success of hepatectomy depends on many factors, 
which include status of the tumor, the patient’s clinical 
status and underlying liver function, and the size of the 
FLR of the patient[12-14]. Aggressive hepatectomy may 
still be beneficial for patients who have advanced HCC 
with large or multiple tumors or intrahepatic venous 
invasion if they are properly selected[15]. Curative 
hepatectomy is the first-line treatment for HCC at many 
centers. The resectability of HCC often rises with the 
volume of the FLR, and therefore different measures 
are employed for increasing such volume. Moreover, 
a larger FLR would probably mean better overall and 
disease-free survival.
SURGICAL RESECTION
In the management of HCC, liver resection for tumor 
clearance is the first-line curative treatment for 
patients with preserved liver function[11,14,16]. Major 
hepatectomy can be performed safely nowadays with 
careful patient selection[12,14], better understanding of 
the liver anatomy[17], improvement of surgical techni-
ques, and advances of surgical instruments. Widely 
adopted techniques include the hanging maneuver[18], 
the anterior approach for avoidance of mobilization and 
rupture of large tumors[19,20], the Pringle maneuver[21], 
and meticulous control of central venous pressure for 
reduction of reduce blood loss[22]. Widely employed 
instruments include Cavitron Ultrasound Surgical Aspirator, 
hydrojet[23,24], the Harmonic scalpel, LigaSure, Harmonic 
Ace, and Thunderbeat[25]. Although complications 
and perioperative mortalities still occur, the rates are 
acceptable[13,14,26,27]. However, major hepatectomy may 
not be suitable for patients with marginal liver function 
or a relatively small FLR. The University of Hong Kong 
uses indocynaine green clearance test as an important 
tool to assess their patients’ preoperative liver function[28]. 
Unfortunately, there is no perfect test for the prediction 
of postoperative mortality[29,30]. For risk stratification for 
major hepatectomy, usually a combination of assess-
ment modalities is adopted, which usually includes 
measurement of the disease’s Child-Pugh grading, 
indocynaine green clearance test, renal function test by 
creatinine level check, and platelet count.
Location of tumors is a decisive factor in surgical 
planning. The amount of liver removed in hepatectomy 
decides the volume of the liver remnant. Major hepa-
tectomy can only be offered to patients with an adequate 
FLR and adequate post-resection liver function. To 
avoid massive bleeding and vascular insult to the liver, 
preservation or reconstruction of major hepatic veins 
in addition to meticulous surgical skills is needed[29]. A 
patient’s liver volume can be measured by tracing the 
liver contour in the cross-sectional image on computed 
tomography volumetry[31], and a patient’s standard liver 
volume can be derived from his weight and height with 
different formulae[32,33]. The volume of his FLR can then 
be calculated. Patients with cirrhosis have relatively 
poor liver function, and thus need a larger FLR[34-37] to 
lower the risk of liver failure. At The University of Hong 
Kong, for patients who have Child-Pugh A cirrhosis and 
an indocynaine green retention rate ≤ 20% at 15 min, 
an FLR > 30% of the estimated standard liver volume 
is preferred for right hepatectomy, and an FLR > 35% 
of the estimated standard liver volume is preferred for 
extended right hepatectomy or right trisectionectomy. 
Patients who have cirrhosis and an inadequate FLR have 
a high risk of post-hepatectomy liver failure[37,38].
REGENERATION OF LIVER REMNANT
Different types of injury (e.g., ischemia/reperfusion, 
resection) will induce a hypertrophic response called 
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the atrophy-hypertrophy complex in a liver remnant. 
Hypertrophy is simultaneously caused by increased 
endothelial shear stress, hepatocellular swelling, and 
activated growth factors/cytokines due to increased 
portal flow[39]. The idea of portal vein embolization (PVE) 
is to occlude a liver segment or lobule so as to bring 
about its ischemia[40,41] and consequent atrophy, thereby 
inducing hypertrophy of the part of liver not atrophied.
PVE
PVE is indicated for patients who are considered for right 
or extended right hepatectomy but with a relatively 
small FLR. By PVE, the size of an FLR can be increased. 
PVE features the embolization of the ipsilateral side of 
the portal vein which supplies the liver lobe harboring 
the tumor, either in an open or percutaneous manner, 
thereby inducing hypertrophy of the FLR[42,43]. To date, 
there is still no straight value on the minimum volume of 
an FLR which allows major hepatectomy to be performed 
safely. An FLR > 35% of the estimated standard liver 
volume has been recommended for patients with 
cirrhosis, steatosis, or chronic hepatitis[28,36,37,44-48]. PVE is 
rarely required before extended left hepatectomy or left 
trisectionectomy, since the right posterior section usually 
constitutes about 30% of the total liver volume[49,50]. The 
technique for embolizing the segment-4 portal vein is 
crucial; if the vein is not properly blocked, suboptimal 
hypertrophy may results.
Liver volume assessment after PVE
The FLR volume will be reassessed 4-8 wk after 
PVE[51,52]. Rapid growth of the FLR is anticipated in 
the first 3-4 wk. Generally, an 8%-30% enlargement 
over 2-6 wk is expected[43,52-55]. Hypertrophy is usually 
slower in the presence of cirrhosis[56]. Studies comparing 
major hepatectomy with and without preceding PVE 
reported that comparable and even superior long-term 
outcomes were achieved with PVE[45,57-63]. With PVE, 
patients who would have been considered inoperable 
in the past because of their small FLR have the option 
of hepatectomy with reasonable long-term surgical 
outcomes.
Complications of PVE
PVE can be performed in an open or percutaneous 
manner. Open right portal vein ligation often renders 
the subsequent surgery difficult due to vascular or 
fibrotic adhesions around the hilar structure. Open 
transileocolic PVE is performed with cannulation of the 
ileocolic vein in addition to embolization of the right 
portal vein in an antegrade manner or percutaneous 
portal vein cannulation and retrograde embolization. 
Ipsilateral percutaneous PVE is generally preferred 
because of the low invasiveness and an easier access 
to segment-4 portal vein branches[64-66]. Different ways 
of PVE all carry a risk of complication, such as main 
portal vein thrombosis. Prompt surgical intervention or 
anticoagulation is needed if the embolic agent crosses 
the contralateral side of the portal vein, which would 
cause liver failure in the case of bilateral PVE, resulting 
in death[67]. Hemorrhage or catastrophic bleeding at 
the puncture site may also occur, which also requires 
prompt surgical intervention. In addition, PVE induces 
inflammatory response near the hilar structure, which 
may increase the difficulty in dissection in the subse-
quent hepatectomy and raise the surgical risk.
SEQUENTIAL TRANSARTERIAL 
CHEMOEMBOLIZATION AND PVE
PVE can be given to HCC patients with underlying 
cirrhosis, but hepatic regeneration and thus hypertrophy 
of the FLR would be impaired in the presence of 
cirrhosis[68-70]. On the other hand, it is likely that the 
arterial flow increases compensatorily in segments with 
PVE, thereby stimulating tumor progression as HCC is a
hypervascular tumor supplied by the hepatic artery 
blood flow[71-73]. To augment the effect of PVE and 
prevent tumor progression, the treatment sequential 
transarterial chemoembolization and PVE is used[57]. 
Studies comparing patients who received this treatment 
and patients who did not found that patients who did 
showed a higer rate of hypertrophy of FLR and a bigger
increase in their FLR[57,58], and the rate of tumor pro-
gression was lower as tumor necrosis was evident[74]. 
This treatment is not without risk; it could cause ischemic 
parenchymal damage[75], but overall, it is feasible and 
safe, and it allows HCC patients who would otherwise be 
denied hepatectomy to undergo curative resection with 
reasonable postoperative 5-year overall and disease-
free survival[57,58,76]. 
STAGED HEPATECTOMY
Staged hepatectomy is mainly for HCC with bilobar 
involvement and colorectal liver metastasis, and is often 
aided by effective adjuvant chemotherapy[77-79]. In staged 
hepatectomy, two or more planned hepatectomies are 
performed at different time to achieve a R0 resection. It 
is distinguished from unplanned repeat hepatectomies 
for recurrent disease[80]. Its aim is to strike a balance 
between complete tumor removal and preservation of 
the FLR. The chance of postoperative liver failure can 
be reduced if bilobar tumors are removed in a staged 
manner. The preserved portion of the liver should be 
relatively spared by the disease with sufficient FLR and 
adequate vascular inflow and outflow[81]. However, there 
is always the chance that the tumor tissue is cut across 
during the first-stage procedure, resulting in tumor 
spillage and peritoneal metastasis, and rendering the 
planned second-stage procedure unfeasible. Besides, 
tumors may grow despite temporary chemotherapy 
during the hepatic regenerative period, which may 
also preclude further operation. Repeat resection is 
technically demanding, as not only all the dissection 
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Associating Liver Partition and Portal Vein Ligation in 
Staged Hepatectomy (ALPPS) is one of the main surgical 
innovations in recent years. The procedure, which was 
invented by chance, was initially carried out by Dr. 
Hans Schlitt from Germany in an intended extended 
right hepatectomy for hilar cholangiocarcinoma[88]. In 
the surgery, palliative left hepaticojejunostomy was 
performed because the FLR was small, with division 
of the liver parenchyma along the falciform ligament 
and ligation of the right portal vein. On day 8 after the 
surgery, computed tomography was performed. To 
Dr. Schlitt’s surprise, the left lateral section had grown 
enormously in size. The diseased portion of the liver 
was subsequently removed in another surgery. This 
novel technique was later termed “ALPPS”[89]. The idea 
of ALPPS is to speed up hypertrophy of the FLR (the 
left lobe or the left lateral section) by right portal vein 
ligation and in-situ splitting of the intended transection 
surface down to the inferior vena cava (Figure 1). 
Generally, the FLR regenerates to a volume adequate for 
a safe hepatectomy in days.
ALPPS was initially applied to relatively normal 
livers, such as in the case of colorectal liver metastasis. 
Later it was also applied to livers with steatosis or 
cirrhosis[88,90-94]. A 70% increase in FLR volume has 
been reported[95]. ALPPS is better than conventional PVE 
when the rate and the percentage of hypertrophy are 
concerned[96,97]. The shorter the interval between the two 
operations is, the less mature the adhesions would be, 
and hence the second operation would also be easier.
Most of the reported cases of ALPPS are on non-
cirrhotic livers, and there has not been any report on 
the rate of hypertrophy in cirrhotic livers. However, one 
would anticipate that some patients would not have 
adequate hypertrophy of the contralateral side and 
hence the second stage operation is not possible. ALPPS 
carries certain risks. The right hepatic artery could be 
injured, and liver failure could occur after right portal 
vein ligation. The Pringle maneuver would pose a further 
risk of liver injury and is thus not recommended. In the 
first-stage operation, adoption of the anterior approach 
allows liver transection without mobilization of the right 
planes have already been disturbed, adhesiolysis can 
also be very difficult. Adhesiolysis near the liver hilum 
and the inferior vena cava is particularly challenging, as 
massive bleeding may occur. Staged hepatectomy for 
HCC was not common[79]; it was mostly for colorectal 
liver metastasis[78,82-85]. 
TWO-STAGED HEPATECTOMY WITH 
PORTAL VEIN LIGATION
This treatment requires two laparotomies and is also 
mainly for HCC with bilobar involvement and colorectal 
liver metastasis. In the first laparotomy, tumor in the 
liver portion which is designated as the FLR is cleared, 
and portal vein ligation is performed. Other required 
resection such as that of colorectal primary tumor is also 
done in the first laparotomy. The liver parenchyma is 
transected only in the second laparotomy but not in the 
first. The portal vein ligation is to induce hypertrophy 
of the FLR, allowing hepatectomy in the second-stage 
procedure and decreasing the risk of postoperative 
liver failure. Portal vein ligation has been found to be as 
effective as PVE[86]. However, open portal vein ligation 
poses the risk of adhesion formation over the hilum, 
which may increase the difficulty of dissection in the 
second-stage operation.
ASSOCIATING LIVER PARTITION AND 
PORTAL VEIN LIGATION IN STAGED 
HEPATECTOMY
For hepatectomy, one of the limiting factors is inadequate 
volume of the FLR. Although the aforesaid methods are 
effective in inducing hypertrophy of the FLR, it takes 
several weeks for it to reach a satisfactory volume[43]. 
Tumor progression may occur before the FLR is large 
enough for the planned hepatectomy to be conducted. 
If a major vessel such as the ipsilateral portal vein is 
invaded by tumor, the tumor will progress in terms of 
days and contralateral deposition and metastasis of the 
tumor will occur, rendering the tumor inoperable[72,73,87]. 
A B C
Figure 1  Associating Liver Partition and Portal Vein Ligation in Staged Hepatectomy. A: Tumor in the right liver lobe, the future liver remnant (the left liver lobe) 
will be small; B: In stage-1 ALPPS, the right portal vein is ligated, liver transected, inferior vena cava exposed, and gallbladder resected; C: In stage-2 ALPPS, the left 
liver lobe has hypertrophied, the right lobe with tumor is resected, right hepatic artery and right hepatic duct transected and ligated. Green: Bile duct; Red: Hepatic 
artery; Blue: Posterior inferior vena cava and anterior portal vein. ALPPS: Associating Liver Partition and Portal Vein Ligation in Staged Hepatectomy.
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lobe, thereby minimizing adhesion formation[98], and 
the hilar plate is left untouched so as to minimize the 
chance of biliary complication. Bile leakage from the 
transection surface can result in biloma and increases 
the chance of infection and thus the risk of sepsis, which 
may forbid the second-stage operation. ALPPS is very 
technically challenging and demanding, and therefore 
should not be carried out by inexperienced surgeons.
Indications for ALPPS
ALPPS should be carried out with a curative intent. It is 
indicated for patients who have a large tumor load and 
a marginal FLR[96], even with tumor invasion of major 
vessels, such as the portal vein[92]. ALPPS renders some 
inoperable tumors potentially operable.
Morbidity and mortality after ALPPS
Complication and mortality are inevitable with any 
surgery; ALPPS is no exception. Perioperative mortality 
rates of 12%-28% have been reported, which are 
overall higher than those of conventional major 
hepatectomy[95,96,99,100]. A complication rate high at 
50% has been recorded[99,101]. Complications include 
ascites, bile leakage, persisting cholestasis and sepsis, 
wound infection, and other inflammatory and infective 
complications. ALPPS increases operability at the price 
of a heightened morbidity and mortality. Keeping 
morbidity and mortality at the minimum requires careful 
patient selection, meticulous surgical technique, and 
accurate decision as to proceeding to the second-stage 
operation or not.
The long-term outcome of ALPPS is still unknown. 
Long-term overall survival and disease-free survival 
are still pending. Further studies as well as input from 
different centers are required but not yet available. 
However, ALPPS has improved the operative rate, and 
it is hoped that it will improve the overall and disease-
free survival of patients. Nonetheless, larger trials are 
needed to document its efficacy especially for those 
patient with HCC and background cirrhosis.
CONCLUSION
There are revolutional changes of surgical methods to 
increase the resectability of HCCs, and various ways to 
increase the volume of the FLR of patients considered 
for major hepatectomy have been developed. Improve-
ment in surgical techniques also allows patients to 
benefit from surgical resection with safety. Treatment 
modalities are always evolving for the better. Hopefully, 
ALPPS will continue to develop and long-term results 
will be available in the near future.
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